Semaglutide

Typical Range

For Wegovy (chronic weight management), the FDA-labeled titration is 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, reaching the maintenance 2.4 mg weekly dose at week 17. For Ozempic (type 2 diabetes), the schedule is 0.25 mg weekly for 4 weeks (a non-therapeutic initiation dose), then 0.5 mg, with escalation to 1.0 mg and 2.0 mg as needed for glycemic targets. Rybelsus (oral) is dosed at 3 mg daily for 30 days, then 7 mg, with optional escalation to 14 mg daily. The oral Wegovy formulation approved in late 2025 is 25 mg daily following the OASIS-4 protocol.

Frequency

Once weekly by subcutaneous injection for Ozempic and Wegovy, on the same day each week with or without regard to meals. Rybelsus and oral Wegovy are taken once daily on an empty stomach with no more than 4 ounces of plain water, followed by a 30-minute fast before food, other liquids, or other oral medications — this fasting window is necessary for SNAC-mediated absorption and is not optional.

Timing Considerations

Cycle Length

Semaglutide is intended for indefinite chronic use in both its diabetes and obesity indications; it is not a cycled intervention. STEP-1 follow-up data show that roughly two-thirds of lost body weight is regained within a year of discontinuation, and metabolic parameters including HbA1c, blood pressure, and lipids trend back toward baseline. The operating assumption from the trial program and clinical guidelines is that the condition being treated (obesity, type 2 diabetes) is chronic, and withdrawal of therapy removes the pharmacological effect without leaving durable physiologic changes.

Protocol Notes

All injectable semaglutide products are supplied as pre-filled multi-dose pen injectors — there is no reconstitution step and no vial-and-syringe preparation required. Injection sites are the abdomen, thigh, or upper arm, and rotation across sites is advised to minimize local reactions; injection does not need to coincide with meals. The slow 16-week titration to 2.4 mg for Wegovy is driven primarily by GI tolerability: nausea, early satiety, and constipation cluster at dose transitions and typically attenuate within 1–2 weeks at each step, which is why skipping or compressing the schedule tends to worsen dropout rather than accelerate efficacy. Rybelsus represents the first and for several years only oral GLP-1 and requires the rigid fasting window described above; skipping the 30-minute wait or taking it with coffee, juice, or food substantially reduces absorption.

Onset

Appetite suppression and reduced food reward are typically reported within the first several days of initiation, even at the sub-therapeutic 0.25 mg dose. Measurable weight loss and HbA1c improvement appear within 2–4 weeks. Full pharmacological effect requires completing the titration; STEP-1 and SUSTAIN data show that most of the weight-loss and glycemic benefit accrues during months 4–12 once the maintenance dose is reached.

Peak Effect

In STEP-1 (Wegovy, 68 weeks), mean weight loss at the 2.4 mg maintenance dose was approximately 14.9%, with the curve still sloping downward at trial end; STEP-5 extended follow-up to 104 weeks and showed weight loss plateau around 15.2% at roughly month 60 weeks. For Ozempic in SUSTAIN-6, HbA1c reductions of ~1.0–1.5 percentage points were reached by month 4–6 and sustained. The general clinical observation is that weight loss curves plateau in the 12–18 month range for most responders at a given dose.

After Discontinuation

The STEP-1 extension trial provided the clearest discontinuation data: among participants who stopped semaglutide 2.4 mg and lifestyle intervention at week 68, approximately two-thirds of lost body weight was regained within the following year, and cardiometabolic improvements (blood pressure, HbA1c, lipid markers) largely reverted toward baseline. The kinetics reflect both pharmacology (the ~1-week half-life means the drug clears within roughly 5 weeks of the last dose) and the underlying biology of obesity as a chronic condition in which adipose set-points reassert once the pharmacological signal is removed.

Bloodwork & Labs

• •HbA1c — the primary glycemic endpoint; rechecked every 3 months
• •Fasting glucose and fasting insulin (HOMA-IR) — pairs well with HbA1c for insulin-resistance tracking
• •Lipid panel (total cholesterol, LDL, HDL, triglycerides) — triglycerides typically respond within 12 weeks
• •ALT and AST — NAFLD-adjacent; often improve as weight drops
• •Lipase and amylase at baseline — pancreatitis is rare but real, and baseline values anchor any later rise

Functional & Performance Tests

• •Body weight (same scale, same time of day, weekly at home)
• •Waist circumference — more sensitive to visceral fat than scale weight alone
• •Home blood pressure cuff — systolic typically falls 4–6 mmHg
• •Resting heart rate (wearable) — expect a modest rise of 2–4 bpm
• •DEXA scan if accessible — tracks lean-mass preservation, which is the quality-of-loss question

When to Test

Baseline, 12 weeks, 24 weeks, then annually while on therapy. Weight and waist weekly at home.

Interpretation & Notes

The STEP and SUSTAIN trials set clear expectations: roughly 15% body weight loss and a 1.5–2.0 point HbA1c drop by week 68 at 2.4 mg. The most useful early checkpoint is 5% weight loss by week 16 — that's the clinical 'responder' threshold, and patients who miss it rarely catch up without dose changes. Lean-mass loss averages 25–40% of total weight lost, so the real 6-month question isn't 'did I lose weight' but 'did I lose the right weight' — DEXA, resistance training, and adequate protein are the levers. If lipase exceeds roughly 3x the upper limit of reference or you develop persistent upper-abdominal pain, stop and see a clinician. Panels are widely available direct-to-consumer via LabCorp, Quest, Marek Health, and Ulta Lab Tests; interpret results with a clinician before adjusting dose.

United States

Semaglutide is FDA-approved as Ozempic (2017) and Rybelsus (2019) for type 2 diabetes, as Wegovy (2021) for chronic weight management in adults and adolescents aged 12+ with obesity, and as of late 2025 in an oral Wegovy formulation following OASIS-4. It additionally carries an FDA indication for reducing MACE in adults with established cardiovascular disease and obesity/overweight (SELECT, 2024). There are no FDA-approved generic semaglutide products as of early 2026; the patent landscape protects Novo Nordisk's exclusivity into the late 2020s. Compounded semaglutide — marketed heavily during the 2022–2024 branded-product shortage — lost its shortage-list status in February 2025, meaning traditional 503A compounding of semaglutide is no longer permitted outside narrowly defined clinical circumstances. 503B outsourcing facilities face tighter restrictions as well.

International

Semaglutide is authorized by the EMA (Ozempic, Rybelsus, Wegovy), the UK MHRA, Health Canada, and Australia's TGA for parallel indications. Availability and reimbursement vary considerably: NHS coverage in the UK for Wegovy is restricted by NICE criteria, and several European payers have tightened obesity-indication coverage relative to diabetes coverage. Compounded and grey-market sourcing is widespread but legally precarious in most jurisdictions.

Sports & Competition

Semaglutide is not currently listed by name on the WADA Prohibited List. However, WADA has signaled increasing scrutiny of GLP-1 agonists in weight-category sports, where rapid body mass reduction could confer competitive advantage. Athletes should consult their governing body before use, as TUE requirements and sport-specific rules evolve.